MG-K10

DRUG3 trials

Sponsors

Shanghai Mabgeek Biotech.Co.Ltd

Conditions

AsthmaAtopic Dermatitis

Phase 1

A Study of MG-K10 in Subjects With Asthma

Shanghai Mabgeek Biotech.Co.LtdAsthma

Start: 2022-07-05End: 2024-06-20Target: 180Updated: 2023-08-21

IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients

RecruitingNCT06765005

Shanghai Mabgeek Biotech.Co.LtdAtopic Dermatitis

Start: 2024-07-19End: 2025-07-31Target: 24Updated: 2025-01-09

Phase 2

A Study of MG-K10 in Subjects With Atopic Dermatitis

Shanghai Mabgeek Biotech.Co.LtdAtopic Dermatitis

Start: 2022-08-31End: 2024-05-26Target: 163Updated: 2024-02-23

Related Papers

Phase Ib/ <scp>II</scp> Study of Preliminary Efficacy, Safety and Pharmacodynamics of <scp>MG</scp> ‐ <scp>K10</scp> , a Humanised Monoclonal Antibody Targeting <scp>IL</scp> ‐ <scp>4Rα</scp> , in Adult Chinese Patients With Asthma

Clinical & Experimental Allergy2026-05-29